1 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

  • You can purchase this item in Pay Per ViewPay per View - FAQ : 33,00 € Taxes included to order
    Pages Iconography Videos Other
    12 1 0 0

Bulletin du Cancer
Volume 102, n° 11
pages 946-957 (novembre 2015)
Doi : 10.1016/j.bulcan.2015.07.007
Received : 7 April 2015 ;  accepted : 10 July 2015
Prise en charge des myélodysplasies
Management of myelodysplastic syndromes

Matthieu Duchmann 1, Pierre Fenaux 2, Thomas Cluzeau 3, 4,
1 Institut Gustave-Roussy, service d’hématologie, 94805 Paris, France 
2 Université Paris 7, Assistance publique des Hôpitaux de Paris, hôpital Saint-Louis, service d’hématologie séniors, 75010 Paris, France 
3 Assistance publique des Hôpitaux de Paris, hôpital Saint-Louis, service d’hématologie, 75010 Paris, France 
4 Centre méditerranéen de médecine moléculaire, Inserm U1065, 06204 Nice, France 

Thomas Cluzeau, Centre méditerranéen de médecine moléculaire, Inserm U1065, bâtiment ARCHIMED, 151, route Saint-Antoine-de-Ginestière, 06204 Nice, France.

Les syndromes myélodysplasiques sont des maladies hétérogènes, dont la caractérisation moléculaire est très récente. Une meilleure connaissance des facteurs pronostiques, l’amélioration des traitements, notamment un plus grand accès à l’allogreffe de cellules souches et l’arrivée de nouvelles molécules (les agents hypométhylants [azacitidine et décitabine] et le lénalidomide) ont amélioré la prise en charge des patients.

The full text of this article is available in PDF format.

Myelodysplastic syndromes are heterogeneous diseases whose molecular characteristics have only been identified in recent years. Better identification of prognostic factors, larger access to allogeneic stem cell transplantation and the advent of new drugs notably hypomethylating agents (azacitidine, decitabine) and lenalidomide have improved patient outcome.

The full text of this article is available in PDF format.

Mots clés : Syndromes myélodysplasiques, Traitement, Caractérisation, Moléculaire, Cytogénétique

Keywords : Myelodysplastic syndrome, Treatment, Characterization, Molecular, Cytogenetic

© 2015  Société Française du Cancer@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline